Work

Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor

Year: 2026

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-25-2916

Authors: Hyun-Woong Cho, Jeong-Yeol Park, Myong Cheol Lim, Byoung-Gie Kim, Seungbong Han, Min Chul Choi, Jae-Weon Kim, Dae Hoon Jeong, Hae Seo, Jungmin Choi, E. Pujade-Lauraine, Jung-Yun Lee

Institutions: Asan Medical Center, University of Ulsan, National Cancer Center, Samsung Medical Center, Sungkyunkwan University, Korea University, Seoul National University, Inje University Busan Paik Hospital, Arcagy Gineco, Yonsei University, Yonsei University Health System

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Korea University, National Cancer Center, Ministry of Science and ICT, South Korea

Awards: G4135880262, G5634268155, G7443792616

OpenAlex ID: W7126022536

FWCI: 2.68

Cites: 41

Cited by: 1

Related to: